ReEngage Therapeutics Expands Sponsored Research Agreement to Develop ACSS2 Inhibitors for Chemorefractory Cancers
Expansion adds Co-Principal investigator that Broadens Collaboration into Ovarian and Urologic Cancers HOUSTON, TX, UNITED STATES, May 18, 2026 /EINPresswire.com/ -- ReEngage Therapeutics, a clinical-stage pharmaceutical company combatting …